This integrated approach combining targeted PI3K inhibition and advanced nanocarrier technology represents a significant advance in addressing the challenges associated with IAV treatment, paving the way for further exploration of these strategies to combat infectious diseases. This evidence concerns the gene PIK3CA and infectious disease.